Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8417259 | 0.78 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1698550 | 0.73 | SMN1; SMN2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10644061 | 0.70 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8723363 | 0.70 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16568461 | 0.70 | MGLL (0.38) | — | |
| SCHEMBL10903416 | 0.70 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL948021 | 0.70 | CHRM2 (0.57) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1536266 | 0.69 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22372501 | 0.69 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19286980 | 0.69 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801633-A1 | CAMPTOTHECIN CONJUGATES | Seagen Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA GMBH (DE) | 2024-02-08 | — | — | US | disclosed |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-02-02 | — | — | US | disclosed |
| EP-2087910-B1 | Polymeric prodrugs | ASCENDIS PHARMA GMBH (DE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3922267-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-12-15 | — | — | EP | disclosed |
| EP-2596805-B1 | Prodrug comprising a drug-linker conjugate | ASCENDIS PHARMA AS (DK) | 2021-10-27 | — | — | EP | disclosed |
| US-20210283264-A1 | Polymeric Prodrugs with a Self-Immolative Linker | ASCENDIS PHARMA GMBH (DE) | 2021-09-16 | — | — | US | disclosed |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-07-22 | — | — | US | disclosed |
| EP-3801633-A1 | CAMPTOTHECIN CONJUGATES | Seagen Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3085388-B1 | HYPERBRANCHED POLYMER CONJUGATES VIA NON-ENZYMATIC CLEAVABLE LINKER | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2021-04-07 | — | — | EP | disclosed |
| WO-2005099768-A2 | POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER | COMPLEX BIOSYSTEMS GMBH (DE) | 2005-10-27 | — | — | WO | disclosed |
| EP-1579873-A1 | Polymeric prodrugs | Complex Biosystems GmbH (DE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1525890-A1 | Protein-Proteophore complexes | Complex Biosystems GmbH (DE) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005034909-A2 | HYPERBRANCHED POLYMER CONJUGATES VIA NON-ENZYMATIC CLEAVABLE LINKER | COMPLEX BIOSYSTEMS GMBH (DE) | 2005-04-21 | — | — | WO | disclosed |
| EP-1093383-B1 | DRUG DELIVERY SYSTEM COMPRISING A HOMEOBOX PEPTIDE AND A CYTOTOXIC OR ANTINEOPLASTIC DRUG | CYCLACEL LTD (GB) | 2004-10-13 | — | — | EP | disclosed |
| US-20030119735-A1 | Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. | CYCLACEL LIMITED OF UNITED KINGDOM | 2003-06-26 | — | — | US | disclosed |
| US-6472507-B1 | Carrier based drug delivery system | CYCLACEL LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | CHRM2 4578/4885CHRM4 4543/4885CHRM5 4616/4885 |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CHRM2 576/4885CHRM4 1331/4885CHRM5 1318/4885 |
| US-20030119735-A1 | Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. | CDYL, CDYL2, DAXX | CHRM2 4369/4885CHRM4 3601/4885CHRM5 3864/4885 |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | CHRM2 4774/4885CHRM4 4775/4885CHRM5 4834/4885 |
| US-20210283264-A1 | Polymeric Prodrugs with a Self-Immolative Linker | PAICS, MPI, GPI | CHRM2 2806/4885CHRM4 1994/4885CHRM5 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.